Janssen reaches Akeega approval milestone
Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer - News - PharmaTimes
Source: pharmatimes.com
Gerhardt Attard News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gerhardt Attard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gerhardt Attard Today - Breaking & Trending Today
Niraparib/Abiraterone Acetate Combo Approved in Europe for BRCA1/2+ mCRPC
The European Commission has granted marketing authorization to the dual action tablet comprised of niraparib and abiraterone acetate to be administered with prednisone or prednisolone in adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.
Source: onclive.com
Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023
Source: marketscreener.com
Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com ... | April 21, 2023
Source: marketscreener.com
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Veracyte, Inc. today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary ... | February 1, 2023
Source: marketscreener.com